Further to DrugAlert vol 875, HPS Pharmacies wish to advise that Pfizer is continuing to experience a supply interruption for Heparin as follows:

Heparin Sodium
Heparin sodium 5000IU/5mL
ARTG 49232

The supply interruption for boxes of 10 ampoules is expected to resolve by end-May 2024, and end-June 2024 for boxes of 50 ampoules.

Internationally registered alternatives have been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that one of the S19A alternatives contains a preservative, while the Australian-registered product is preservative-free. Alternatives may also be accessed via the Special Access Scheme (SAS). There is currently a considerable lead time for accessing these alternative products.

Other presentations that are available to order as normal include:

  • DBL Heparin Sodium 5000IU/0.2mL (5 amps)
  • DBL Heparin Sodium 1000IU/1mL (50 amps)
  • DBL Heparin Sodium 5000IU/1mL (5 amps)

Heparin is a high-risk medication. Additional care is recommended when selecting products, particularly when the packaging may be unfamiliar.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates